Crespo Blas Coll - 01 Mar 2025 Form 4 Insider Report for Structure Therapeutics Inc. (GPCR)

Role: CHIEF MEDICAL OFFICER
Signature: /s/ Jun Yoon, Attorney-in-Fact
Issuer symbol: GPCR
Transactions as of: 01 Mar 2025
Net transactions value: -$19,565
Form type: 4
Filing time: 03 Jul 2025, 17:15:14 UTC
Previous filing: 20 Sep 2024
Next filing: 18 Mar 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Coll Crespo Blas	CHIEF MEDICAL OFFICER	C/O STRUCTURE THERAPEUTICS INC., 601 GATEWAY BLVD., SUITE 900, SOUTH SAN FRANCISCO	/s/ Jun Yoon, Attorney-in-Fact	03 Jul 2025	0002037144

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	GPCR	Ordinary Shares	Tax liability	$9,761	-1,233	-0.56%	$7.92	218,355	01 Mar 2025	Direct	F1, F2
transaction	GPCR	Ordinary Shares	Award	$0	+7,992	+3.7%	$0.000000	226,347	01 Jul 2025	Direct	F1, F3
transaction	GPCR	Ordinary Shares	Tax liability	$9,804	-1,434	-0.63%	$6.84	224,913	01 Jul 2025	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	GPCR	American Depositary Shares	Award	$0	+429	+59%	$0.000000	1,157	21 May 2025	Ordinary Shares	1,287		Direct	F1, F4, F5
holding	GPCR	American Depositary Shares						1,000	01 Mar 2025	Ordinary Shares	3,000		By spouse	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer.
F2	Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award.
F3	On March 15, 2024, the reporting person was granted performance-vesting restricted share units ("PSUs"), each of which represents a contingent right to receive one Ordinary Share of the Issuer, which vest upon satisfaction of certain performance criteria. Certain of the performance criteria was determined to have been met effective July 1, 2025. The shares subject to the PSUs vest as follows: 50% of the shares vested on July 1, 2025 and the remainder will vest on January 1, 2027 subject to the reporting person's Continuous Service (as defined in the Structure Therapeutics Inc. 2023 Equity Incentive Plan) through such vesting date.
F4	Each ADS is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The ADSs have no expiration date.
F5	Voluntary reporting of the acquisition of 429 ADSs by the Reporting Person on May 21, 2025 pursuant to the Issuer's Employee Share Purchase Plan.